Cognitive Markers of Response to Treatment in Resistant Depression

Study Overview
=================
Brief Summary
-----------------
Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment. The aim of this study is to investigate the relation between the cognitive changes and the remission of depressive symptoms in patients with recurrent depression (Stage 2 of Thase and Rush classification). To explore the dynamics of cognitive dimension associated to clinical and functional remission, the investigators will observe neurocognitive functioning before and after introducing a new antidepressive therapy.

Official Title
-----------------
Cognitive Markers of Response to Treatment in Resistant Depression

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Behavioral: Recurrent depression


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be aged from 40 to 70, with a major depressive episode diagnosis with a 2 stage degree of resistance. Exclusion Criteria: Patients with major depressive episode during more of 12 months Alzheimer dementia or related disease (CIM 10) Score Hamilton Depression Rating Scale (HDRS) < 18

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Recurrent depression|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinic assessments: Score BDI - II | The investigators will conduct clinical assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be clinically assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy. | Change from the baseline score BDI-II at 12 months after introducing the new therapy | 
| Functional assessments : Score Sheehan Disability Scale (SDS) | The investigators will conduct functional assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be functional assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy. | Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy | 
| Neuropsychologic assessments: M.M.S.E. (Mini Mental Score Evaluation) | The investigators will conduct neuropsychologic assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; A complete assessment will be done 6 months and 12 months after introducing the new therapy. | Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy |